GIP + Glucagon Simultaneously activates GIP receptors (enhancing insulin secretion and fat metabolism) and glucagon receptors (increasing energy expenditure and lipolysis)
Seasonal timing adjustments Some experienced researchers adjust their timing strategy seasonally
In 2009, Novo Nordisk's Liraglutide (Victoza) was approved by the EMA and in January 2010 by the FDA for the treatment of type 2 diabetes
These findings align closely with prior cardiovascular outcome trials and solidify the evidence base by demonstrating consistent benefits in broader patient populations treated in clinical practice
Semaglutide works on GLP-1 only, while Retatrutide works on GLP-1, GIP, and glucagon together, so labs study it for stronger effects on appetite, insulin, and energy burn
Food and Drug Administration (FDA) in 2011